Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Moderna (MRNA) 10K Form and Latest SEC Filings 2026

Moderna logo
$47.22 -0.90 (-1.88%)
As of 03:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Moderna SEC Filings & Recent Activity

Moderna (NASDAQ:MRNA) has submitted 952+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Moderna's financial statements. The most recent filing was a Form 144 submitted on May 21, 2026.

Form 4
Moderna, Inc. Reports Ownership Change on May. 8, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Moderna Files Current Report on May. 11, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Moderna Files Quarterly Report on Aug. 1, 2025

The 10-Q contains Moderna's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Moderna SEC Filing History

Browse Moderna's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/15/2026 8:47 AM
Hoge Stephen (1760669) Reporting
Moderna (1682852) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/11/2026 5:06 AM
Moderna (1682852) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2026 3:59 PM
Moderna (1682852) Issuer
Nader Francois (1365343) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2026 4:02 PM
Moderna (1682852) Issuer
NABEL ELIZABETH G (1619929) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2026 4:04 PM
Horning Sandra (1638709) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2026 4:06 PM
Hussain Abbas (1821956) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2026 10:24 AM
Moderna (1682852) Subject
SAGAN PAUL (1035440) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/04/2026 4:39 PM
Horning Sandra (1638709) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 4:25 PM
Hussain Abbas (1821956) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 4:36 PM
Moderna (1682852) Issuer
Rubenstein David M. (1543895) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 3:59 PM
Moderna (1682852) Issuer
NABEL ELIZABETH G (1619929) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 3:44 PM
Moderna (1682852) Issuer
Tallett Elizabeth E (1192460) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 3:48 PM
Moderna (1682852) Issuer
Nader Francois (1365343) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 10:44 AM
Hussain Abbas (1821956) Reporting
Moderna (1682852) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/30/2026 10:30 AM
Moderna (1682852) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/06/2026 3:45 PM
Mock James M (1736359) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 3:24 PM
Klinger Shannon Thyme (1866132) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 8:56 AM
Klinger Shannon Thyme (1866132) Reporting
Moderna (1682852) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/25/2026 3:49 PM
Hoge Stephen (1760669) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/23/2026 9:26 AM
Hoge Stephen (1760669) Reporting
Moderna (1682852) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/13/2026 3:41 PM
Mock James M (1736359) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 6:02 AM
Moderna (1682852) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/09/2026 9:48 AM
BAILLIE GIFFORD & CO (1088875) Filed by
Moderna (1682852) Subject
Form SCHEDULE 13G/A
02/06/2026 12:10 PM
FMR LLC (315066) Filed by
Moderna (1682852) Subject
Form SCHEDULE 13G/A
02/05/2026 12:31 PM
Moderna (1682852) Subject
Form SCHEDULE 13G
01/12/2026 6:01 AM
Moderna (1682852) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/06/2026 3:36 PM
Mock James M (1736359) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 8:04 AM
Moderna (1682852) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/16/2025 6:31 AM
Moderna (1682852) Subject
Form SC TO-I/A
12/15/2025 8:00 AM
AFEYAN NOUBAR (1222012) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 7:59 AM
Bancel Stephane (1443340) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 3:30 PM
Flagship Pioneering Inc. (1400240) Reporting
Moderna (1682852) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2025 3:16 PM
Hussain Abbas (1821956) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 9:26 AM
Hussain Abbas (1821956) Reporting
Moderna (1682852) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/08/2025 3:44 PM
Mock James M (1736359) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2025 3:40 PM
Klinger Shannon Thyme (1866132) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2025 3:44 PM
Hoge Stephen (1760669) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2025 3:47 PM
Klinger Shannon Thyme (1866132) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 3:19 PM
Hoge Stephen (1760669) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 3:24 PM
Klinger Shannon Thyme (1866132) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 3:27 PM
Mock James M (1736359) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
The Iran War Just Broke the Gold Market (Ad)

The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged… Defense stocks exploded…And gold ripped past $5,000.tc pixel

You can see the evidence — and the ticker symbol — here >>>
11/24/2025 3:29 PM
Moderna (1682852) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/20/2025 6:12 AM
Moderna (1682852) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2025 7:21 AM
Moderna (1682852) Subject
Form SC TO-I
11/12/2025 4:21 PM
Moderna (1682852) Subject
Form SC TO-C
11/06/2025 4:15 PM
Moderna (1682852) Subject
Form SC TO-C
11/06/2025 6:03 AM
Moderna (1682852) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/05/2025 10:40 AM
FMR LLC (315066) Filed by
Moderna (1682852) Subject
Form SCHEDULE 13G/A
10/21/2025 3:33 PM
Moderna (1682852) Subject
Form SC TO-C
10/15/2025 7:45 AM
Moderna (1682852) Filer
Form DEF 14A
10/10/2025 9:42 AM
Moderna (1682852) Subject
Form SC TO-C
10/06/2025 3:23 PM
Mock James M (1736359) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/06/2025 3:14 PM
Hussain Abbas (1821956) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2025 8:20 AM
Moderna (1682852) Subject
Form SC TO-C
10/03/2025 6:30 AM
Moderna (1682852) Filer
Form PRE 14A
09/02/2025 4:26 PM
Klinger Shannon Thyme (1866132) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2025 4:20 PM
Hoge Stephen (1760669) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 3:13 PM
Mock James M (1736359) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 3:06 PM
Hoge Stephen (1760669) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 3:10 PM
Klinger Shannon Thyme (1866132) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/01/2025 3:03 PM
Moderna (1682852) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/01/2025 6:02 AM
Moderna (1682852) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/07/2025 3:59 PM
Mock James M (1736359) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2025 9:06 AM
Hussain Abbas (1821956) Reporting
Moderna (1682852) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/09/2025 3:20 PM
Klinger Shannon Thyme (1866132) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2025 3:36 PM
Hoge Stephen (1760669) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2025 4:16 PM
Mock James M (1736359) Reporting
Moderna (1682852) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Moderna SEC Filings - Frequently Asked Questions

Moderna (MRNA) has submitted 952+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Moderna's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Moderna's financial statements page.

The most recent filing was a Form 144 submitted on May 21, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:MRNA) was last updated on 5/21/2026 by MarketBeat.com Staff.
From Our Partners